Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Peter M. Voorhees, Jesús G. Berdeja et al.|Journal of Clinical Oncology|2025Cited by 107
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Tamia Nguyen et al.|Blood|2023Cited by 99
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Blood|2023Cited by 4
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Transplantation and Cellular Therapy|2024Cited by 1